# BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting
Canonical URL: https://biopharmsignal.com/news/BYSI/beyondspring-announces-poster-presentation-at-2025-asco-annual-meeting-b676b0a1
Ticker: BYSI
Company: BeyondSpring, Inc.
Source: BeyondSpring, Inc.
Published: 2025-05-28 11:00 EST
## Summary

BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global...

## Article Body
BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing cancer therapies, today announces that it will have a poster presentation on 303 Study, the investigator-initiated study supported by Merck (known as MSD outside of the United States and Canada) and BeyondSpring in 2L/3L NSCLC who progressed on PD-1/PD-L1 inhibitors at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting , taking place on May 30 through June 3 in Chicago, IL.

​​ Presentation details are as follows:

Title: Phase 2 Study of Pembrolizumab (Pembro) plus Plinabulin (Plin) and Docetaxel (Doc) for Patients (Pts) with Metastatic NSCLC after Progression on First-line Immune Checkpoint Inhibitor Alone or Combination Therapy: Initial Efficacy and Safety Results on Immune Re-sensitization

Presenter / Author : Yan Xu, Minjiang Chen, Xiaoxing Gao, Xiaoyan Liu, Jing Zhao, Wei Zhong, RuiLi Pan, Mengzhao Wang

Presentation Time : Saturday, May 31, 2025, at 1:30PM to 4:30PM CDT

Location : McCormick Place Convention Center

Session / Track : Lung Cancer – Non-Small Cell Metastatic

Abstract Number: 8560

Poster Board Number: 40

About BeyondSpring BeyondSpring (NASDAQ: BYSI) is a clinical-stage biopharmaceutical company developing first-in-class therapies for high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in NSCLC and a range of cancer indications. Plinabulin’s novel mechanism of action as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering a unique approach to resensitizing tumors to checkpoint inhibitors. Learn more at beyondspringpharma.com .

About 303 Study 303 Study is an open-label, single-arm Phase 2 Study of Plinabulin plus docetaxel and pembrolizumab for previously treated patients with metastatic NSCLC and progressive disease after anti-PD-(L)1 inhibitor alone or in combination with platinum-doublet chemotherapy. This study evaluates the efficacy and safety of this triple combination and is being conducted at Peking Union Medical College Hospital, Beijing, China with Dr. Mengzhao Wang, Chief of the Department of Respiratory and Critical Care Medicine, as the principal investigator and with Merck. The sample size of the study is 47 patients and all have been enrolled. The primary endpoint is investigator-based ORR (RECIST 1.1). The secondary endpoints include PFS, OS, DoR, and safety. The regimen includes Pembrolizumab 200 mg IV every 3 weeks (Q3W) on Day 1, Docetaxel 75 mg/m2 IV Q3W on Day 1 and Plinabulin 30mg/m2 IV Q3W on Day 1 in a 21-day cycle. The study is funded by Merck’s Investigator Studies Program and BeyondSpring with provision of study drug and financial support. The registration number is NCT05599789 on clinicaltrials.gov.

Investor Contact: IR@beyondspringpharma.com

Media Contact: PR@beyondspringpharma.com
## Recent Company News
- 2026-06-04 11:00 EST — [BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value](https://biopharmsignal.com/news/BYSI/beyondspring-announces-leadership-transition-to-deliver-focused-execution-on-its-7cdf7bc8) — Source: BeyondSpring, Inc.
- 2026-06-02 11:00 EST — [BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026](https://biopharmsignal.com/news/BYSI/beyondspring-presents-the-latest-update-of-a-phase-2-study-demonstrating-durable-b6c4b5ec) — Source: BeyondSpring, Inc.
- 2026-05-18 11:00 EST — [BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting](https://biopharmsignal.com/news/BYSI/beyondspring-announces-poster-presentation-at-2026-asco-annual-meeting-121bfb8e) — Source: BeyondSpring, Inc.
- 2026-05-13 11:00 EST — [BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/BYSI/beyondspring-reports-first-quarter-2026-financial-results-and-provides-corporate-7bef7d23) — Source: BeyondSpring, Inc.
- 2026-04-22 11:00 EST — [BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs](https://biopharmsignal.com/news/BYSI/beyondspring-reports-compelling-new-data-plinabulin-advances-both-the-anticancer-ba2782eb) — Source: BeyondSpring, Inc.
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)